Antibody Information
General Information of This Antibody
| Antibody ID | ANTI0SGJCG |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | 99961.1 |
|||||
| Synonyms |
99961.1
Click to Show/Hide
|
|||||
| Antigen Name | Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
CN119371541A 99961.1-MMAE [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
11.08%
|
|||
| Method Description |
Cell line-derived xenograft models were established in nude mice by subcutaneous injection of 1x106 (HT-29) tumor cells, and treatment with 0.4mg/kg 99961.1-MMAE (BIWƨ) was initiated after tumor volume about 100mm3. Determined tumor volume after the experiment, measured at day 51.
|
||||
| In Vivo Model | HT-29 xenograft model | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
15.90%
|
|||
| Method Description |
Cell line-derived xenograft models were established in nude mice by subcutaneous injection of 1x106 (HT-29) tumor cells, and treatment with 2mg/kg 99961.1-MMAE (BIWƨ) was initiated after tumor volume about 100mm3. Determined tumor volume after the experiment, measured at day 51.
|
||||
| In Vivo Model | HT-29 xenograft model | ||||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
34.60%
|
|||
| Method Description |
Cell line-derived xenograft models were established in female nude mice (Balb/C),by subcutaneous injection of 1x107 (Jeko-1) tumor cells,and treatment with 2.5 (D15)/3.5 (D29)mpk 99961.1-MMAE (Q2WƦ)was initiated after tumor volume about 100mm3. Determined tumor volume after the experiment, measured at day 41.
|
||||
| In Vivo Model | Jeko-1 xenograft model | ||||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
37.81%
|
|||
| Method Description |
Cell line-derived xenograft models were established in female nude mice (Balb/C),by subcutaneous injection of 1x106 (A549) tumor cells,and treatment with 10mpk (mg/kg)99961.1-MMAE (BIWƧ)was initiated after tumor volume about 100mm3. Determined tumor volume after the experiment, measured at day 48.
|
||||
| In Vivo Model | A549 xenograft model | ||||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
59.22%
|
|||
| Method Description |
Cell line-derived xenograft models were established in female nude mice (Balb/C),by subcutaneous injection of 1x107 (Jeko-1) tumor cells,and treatment with 2.5mpk (mg/kg) 99961.1-MMAE (QWƧ)was initiated after tumor volume about 100mm3. Determined tumor volume after the experiment, measured at day 41.
|
||||
| In Vivo Model | Jeko-1 xenograft model | ||||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
64.31%
|
|||
| Method Description |
Cell line-derived xenograft models were established in female nude mice (NOD),by subcutaneous injection of 1x107 (MDA-MB-468) tumor cells,and treatment with 10mpk (mg/kg) 99961.1-MMAE (single dose)was initiated after tumor volume about 100mm3. Determined tumor volume after the experiment, measured at day 56.
|
||||
| In Vivo Model | MDA-MB-468 xenograft model | ||||
| Experiment 7 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
67.66%
|
|||
| Method Description |
Cell line-derived xenograft models were established in female nude mice (Balb/C),by subcutaneous injection of 1x106 (MDA-MB-231) tumor cells,and treatment with 5mpk (mg/kg) 99961.1-MMAE (QWƧ)was initiated after tumor volume about 100mm3. Determined tumor volume after the experiment, measured at day 56.
|
||||
| In Vivo Model | MDA-MB-231 xenograft model | ||||
| Experiment 8 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
89.35%
|
|||
| Method Description |
Cell line-derived xenograft models were established in nude mice by subcutaneous injection of 1x106 (HT-29) tumor cells, and treatment with 10mg/kg 99961.1-MMAE (BIWƨ) was initiated after tumor volume about 100mm3. Determined tumor volume after the experiment, measured at day 51.
|
||||
| In Vivo Model | HT-29 xenograft model | ||||
| Experiment 9 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
91.74%
|
|||
| Method Description |
Cell line-derived xenograft models were established in female nude mice (Balb/C),by subcutaneous injection of 1x107 (Jeko-1) tumor cells,and treatment with 10mpk (mg/kg) 99961.1-MMAE (single dose)was initiated after tumor volume about 100mm3. Determined tumor volume after the experiment, measured at day 41.
|
||||
| In Vivo Model | Jeko-1 xenograft model | ||||
| Experiment 10 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
95.77%
|
|||
| Method Description |
Cell line-derived xenograft models were established in female nude mice (Balb/C),by subcutaneous injection of 1x107 (Jeko-1) tumor cells,and treatment with 10mpk (mg/kg) 99961.1-MMAE (QWƧ)was initiated after tumor volume about 100mm3. Determined tumor volume after the experiment, measured at day 41.
|
||||
| In Vivo Model | Jeko-1 xenograft model | ||||
| Experiment 11 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
96.60%
|
|||
| Method Description |
Cell line-derived xenograft models were established in female nude mice (Balb/C),by subcutaneous injection of 1x106 (MDA-MB-231) tumor cells,and treatment with 10mpk (mg/kg) 99961.1-MMAE (QWƧ)was initiated after tumor volume about 100mm3. Determined tumor volume after the experiment, measured at day 56.
|
||||
| In Vivo Model | MDA-MB-231 xenograft model | ||||
| Experiment 12 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
97.86%
|
|||
| Method Description |
Cell line-derived xenograft models were established in female nude mice (Balb/C),by subcutaneous injection of 1x106 (NCI-N87) tumor cells,and treatment with 5mpk (mg/kg) 99961.1-MMAE (QWƧ)was initiated after tumor volume about 100mm3. Determined tumor volume after the experiment, measured at day 51.
|
||||
| In Vivo Model | NCI-N87 xenograft model | ||||
| Experiment 13 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
98.21%
|
|||
| Method Description |
Cell line-derived xenograft models were established in female nude mice (NOD),by subcutaneous injection of 1x107 (MDA-MB-468) tumor cells,and treatment with 5mpk (mg/kg) 99961.1-MMAE (QWƧ)was initiated after tumor volume about 100mm3. Determined tumor volume after the experiment, measured at day 56.
|
||||
| In Vivo Model | MDA-MB-468 xenograft model | ||||
| Experiment 14 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
99.20%
|
|||
| Method Description |
Cell line-derived xenograft models were established in female nude mice (Balb/C),by subcutaneous injection of 1x106 (NCI-N87) tumor cells,and treatment with 10mpk (mg/kg) 99961.1-MMAE (QWƧ)was initiated after tumor volume about 100mm3. Determined tumor volume after the experiment, measured at day 51.
|
||||
| In Vivo Model | NCI-N87 xenograft model | ||||
| Experiment 15 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
100%
|
|||
| Method Description |
Cell line-derived xenograft models were established in female nude mice (NOD),by subcutaneous injection of 1x107 (MDA-MB-468) tumor cells,and treatment with 10mpk (mg/kg) 99961.1-MMAE (QWƧ)was initiated after tumor volume about 100mm3. Determined tumor volume after the experiment, measured at day 56.
|
||||
| In Vivo Model | MDA-MB-468 xenograft model | ||||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
21.22 nM
|
High ROR1 expression (ROR1 +++) | ||
| Method Description |
MDA-MB-468 cell line was plated at 2×105cell/mL, 90uL/well,12 hours later, ADCs (500, 158, 50, 15.8, 5, 1.58, 0.5, 0.158, 0.05nM) were added and incubated for 72h,then 10uL CCK8 (Bimake,B34304)was added to each well and a microplate reader was used for detection OD492.
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-468 cells | CVCL_0419 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
44.56 nM
|
|||
| Method Description |
Jeko-1 cell line was plated at 1×105cell/mL, 90uL/well,12 hours later, ADCs (500, 158, 50, 15.8, 5, 1.58, 0.5, 0.158, 0.05nM) were added and incubated for 72h,then 10uL CCK8 (Bimake,B34304)was added to each well and a microplate reader was used for detection OD492.
|
||||
| In Vitro Model | Mantle cell lymphoma | JeKo-1 cells | CVCL_1865 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
80.79 nM
|
|||
| Method Description |
HT-29 cell line (1×104cell/mL,100uL/well) , the ADCs (2000, 500, 250, 125, 62.5, 31.25, 15.625, 7.813, 1.953nM) were added 12 hours later, and incubated for 96h, then 40uL/well MTS (Promega,G3580) was added to each well and a microplate reader was used for detection OD492.
|
||||
| In Vitro Model | Colon adenocarcinoma | HT-29 cells | CVCL_0320 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
82.09 nM
|
|||
| Method Description |
HT-29 cell line (1×104cell/mL,100uL/well) , the ADCs (2000, 500, 250, 125, 62.5, 31.25, 15.625, 7.813, 1.953nM) were added 12 hours later, and incubated for 96h, then 40uL/well MTS (Promega,G3580) was added to each well and a microplate reader was used for detection OD492.
|
||||
| In Vitro Model | Colon adenocarcinoma | HT-29 cells | CVCL_0320 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
102.8 nM
|
|||
| Method Description |
NCI-H1944 cell line was plated at 1.2×105cell/mL, 90uL/well,12 hours later, ADCs (500, 158, 50, 15.8, 5, 1.58, 0.5, 0.158, 0.05nM) were added and incubated for 72h,then 10uL CCK8 (Bimake,B34304)was added to each well and a microplate reader was used for detection OD492.
|
||||
| In Vitro Model | Lung adenocarcinoma | NCI-H1944 cells | CVCL_1508 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
250.7 nM
|
Moderate ROR1 expression (ROR1++) | ||
| Method Description |
A549 at 1×104cell/mL,100uL/well, 12 hours later,ADCs (2000, 500, 250, 125, 62.5, 31.25, 15.625, 7.813, 1.953nM) were added and incubated for 72h, then 40uL/well MTS (Promega,G3580) was added to each well and a microplate reader was used for detection OD492.
|
||||
| In Vitro Model | Lung adenocarcinoma | A549 cells | CVCL_0023 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
295.6 nM
|
Moderate ROR1 expression (ROR1++) | ||
| Method Description |
A549 at 1×104cell/mL,100uL/well, 12 hours later,ADCs (2000, 500, 250, 125, 62.5, 31.25, 15.625, 7.813, 1.953nM) were added and incubated for 72h, then 40uL/well MTS (Promega,G3580) was added to each well and a microplate reader was used for detection OD492.
|
||||
| In Vitro Model | Lung adenocarcinoma | A549 cells | CVCL_0023 | ||
CO20240013452A2 99961-MMAE [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
11.08%
|
Positive ROR1 expression (ROR1+++/++) | ||
| Method Description |
Female Balb/C nude mice between 6-8 weeks of age were injected subcutaneously withHT-29 cells, when tumors reached appproximately 100 mm^3, animals were matched by tumor volume into treatment or controls groups. The test articles were given by tail vein at a dose (0.4 mg/kg) (BIWƨ).
|
||||
| In Vivo Model | HT-29 xenograft model | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
15.90%
|
Positive ROR1 expression (ROR1+++/++) | ||
| Method Description |
Female Balb/C nude mice between 6-8 weeks of age were injected subcutaneously withHT-29 cells, when tumors reached appproximately 100 mm^3, animals were matched by tumor volume into treatment or controls groups. The test articles were given by tail vein at a dose (2 mg/kg) (BIWƨ).
|
||||
| In Vivo Model | HT-29 xenograft model | ||||
| Experiment 3 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
34.60%
|
Positive ROR1 expression (ROR1+++/++) | ||
| Method Description |
Female Balb/C nude mice between 6-8 weeks of age were injected subcutaneously with Jeko-1 cells, when tumors reached appproximately 100 mm^3, animals were matched by tumor volume into treatment or controls groups. The test articles were given by tail vein at a dose (2.5 mg/kg- D15, 3.5 mg/kg- D29) (Q2WƦ).
|
||||
| In Vivo Model | Jeko-1 xenograft model | ||||
| Experiment 4 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
37.81%
|
Positive ROR1 expression (ROR1+++/++) | ||
| Method Description |
Female Balb/C nude mice between 6-8 weeks of age were injected subcutaneously with A549 cells, when tumors reached appproximately 100 mm^3, animals were matched by tumor volume into treatment or controls groups. The test articles were given by tail vein at a dose (10 mg/kg) (BIWƧ).
|
||||
| In Vivo Model | A549 xenograft model | ||||
| Experiment 5 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
59.22%
|
Positive ROR1 expression (ROR1+++/++) | ||
| Method Description |
Female Balb/C nude mice between 6-8 weeks of age were injected subcutaneously with Jeko-1 cells, when tumors reached appproximately 100 mm^3, animals were matched by tumor volume into treatment or controls groups. The test articles were given by tail vein at a dose (2.5 mg/kg) (QWƧ).
|
||||
| In Vivo Model | Jeko-1 xenograft model | ||||
| Experiment 6 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
64.31%
|
Positive ROR1 expression (ROR1+++/++) | ||
| Method Description |
Female NOD SCID nude mice between 6-8 weeks of age were injected subcutaneously with MDA-MB-4681 cells, when tumors reached appproximately 200 mm^3, animals were matched by tumor volume into treatment or controls groups. The test articles were given by tail vein at a dose (10 mg/kg) once.
|
||||
| In Vivo Model | MDA-MB-468 xenograft model | ||||
| Experiment 7 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
67.66%
|
Positive ROR1 expression (ROR1+++/++) | ||
| Method Description |
Female Balb/C nude mice between 6-8 weeks of age were injected subcutaneously with MDA-MB-231 cells, when tumors reached appproximately 100 mm^3, animals were matched by tumor volume into treatment or controls groups. The test articles were given by tail vein at a dose (5 mg/kg) (QWƧ).
|
||||
| In Vivo Model | MDA-MB-231 xenograft model | ||||
| Experiment 8 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
89.35%
|
Positive ROR1 expression (ROR1+++/++) | ||
| Method Description |
Female Balb/C nude mice between 6-8 weeks of age were injected subcutaneously withHT-29 cells, when tumors reached appproximately 100 mm^3, animals were matched by tumor volume into treatment or controls groups. The test articles were given by tail vein at a dose (10 mg/kg) (BIWƨ).
|
||||
| In Vivo Model | HT-29 xenograft model | ||||
| Experiment 9 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
91.74%
|
Positive ROR1 expression (ROR1+++/++) | ||
| Method Description |
Female Balb/C nude mice between 6-8 weeks of age were injected subcutaneously with Jeko-1 cells, when tumors reached appproximately 100 mm^3, animals were matched by tumor volume into treatment or controls groups. The test articles were given by tail vein at a dose (10 mg/kg) once.
|
||||
| In Vivo Model | Jeko-1 xenograft model | ||||
| Experiment 10 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
95.77%
|
Positive ROR1 expression (ROR1+++/++) | ||
| Method Description |
Female Balb/C nude mice between 6-8 weeks of age were injected subcutaneously with Jeko-1 cells, when tumors reached appproximately 100 mm^3, animals were matched by tumor volume into treatment or controls groups. The test articles were given by tail vein at a dose (10 mg/kg) (QWƧ).
|
||||
| In Vivo Model | Jeko-1 xenograft model | ||||
| Experiment 11 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
96.60%
|
Positive ROR1 expression (ROR1+++/++) | ||
| Method Description |
Female Balb/C nude mice between 6-8 weeks of age were injected subcutaneously with MDA-MB-231 cells, when tumors reached appproximately 100 mm^3, animals were matched by tumor volume into treatment or controls groups. The test articles were given by tail vein at a dose (10 mg/kg) (QWƧ).
|
||||
| In Vivo Model | MDA-MB-231 xenograft model | ||||
| Experiment 12 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
97.86%
|
Positive ROR1 expression (ROR1+++/++) | ||
| Method Description |
Female Balb/C nude mice between 6-8 weeks of age were injected subcutaneously with NCI-N87 cells, when tumors reached appproximately 100 mm^3, animals were matched by tumor volume into treatment or controls groups. The test articles were given by tail vein at a dose (5 mg/kg) (QWƧ).
|
||||
| In Vivo Model | NCI-N87 xenograft model | ||||
| Experiment 13 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
98.21%
|
Positive ROR1 expression (ROR1+++/++) | ||
| Method Description |
Female NOD SCID nude mice between 6-8 weeks of age were injected subcutaneously with MDA-MB-4681 cells, when tumors reached appproximately 200 mm^3, animals were matched by tumor volume into treatment or controls groups. The test articles were given by tail vein at a dose (5 mg/kg) (QWƧ).
|
||||
| In Vivo Model | MDA-MB-468 xenograft model | ||||
| Experiment 14 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
99.20%
|
Positive ROR1 expression (ROR1+++/++) | ||
| Method Description |
Female Balb/C nude mice between 6-8 weeks of age were injected subcutaneously with NCI-N87 cells, when tumors reached appproximately 100 mm^3, animals were matched by tumor volume into treatment or controls groups. The test articles were given by tail vein at a dose (10 mg/kg) (QWƧ).
|
||||
| In Vivo Model | NCI-N87 xenograft model | ||||
| Experiment 15 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
100%
|
Positive ROR1 expression (ROR1+++/++) | ||
| Method Description |
Female NOD SCID nude mice between 6-8 weeks of age were injected subcutaneously with MDA-MB-4681 cells, when tumors reached appproximately 200 mm^3, animals were matched by tumor volume into treatment or controls groups. The test articles were given by tail vein at a dose (10 mg/kg) (QWƧ).
|
||||
| In Vivo Model | MDA-MB-468 xenograft model | ||||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
21.22 nM
|
|||
| Method Description |
ADCs were tested in MDA-MB-468 cells, and were added at final working concentration at 500 nM, 158 nM, 50 nM, 15.8 nM, 5 nM, 1.58 nM, 0.5 nM, 0.158 nM, 0.05 Nm, incubated for 3 days.
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-468 cells | CVCL_0419 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
44.56 nM
|
|||
| Method Description |
ADCs were tested in Jeko-1 cells, and were added at final working concentration at 500 nM, 158 nM, 50 nM, 15.8 nM, 5 nM, 1.58 nM, 0.5 nM, 0.158 nM, 0.05 Nm, incubated for 3 days.
|
||||
| In Vitro Model | Mantle cell lymphoma | JeKo-1 cells | CVCL_1865 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
82.09 nM
|
|||
| Method Description |
ADCs were tested in HT-29 cells, and were added at final working concentration at 2000 nM, 500 nM, 250 nM, 125 nM, 62.5 nM, 31.25 nM, 15.625 nM, 7.813 nM, 1.953 nM, incubated for 4 days.
|
||||
| In Vitro Model | Colon adenocarcinoma | HT-29 cells | CVCL_0320 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
102.8 nM
|
|||
| Method Description |
ADCs were tested in NCI-H1944 cells, and were added at final working concentration at 500 nM, 158 nM, 50 nM, 15.8 nM, 5 nM, 1.58 nM, 0.5 nM, 0.158 nM, 0.05 Nm, incubated for 3 days.
|
||||
| In Vitro Model | Lung adenocarcinoma | NCI-H1944 cells | CVCL_1508 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
295.6 nM
|
|||
| Method Description |
ADCs were tested in A549 cells, and were added at final working concentration at 2000 nM, 500 nM, 250 nM, 125 nM, 62.5 nM, 31.25 nM, 15.625 nM, 7.813 nM, 1.953 nM, incubated for 3 days.
|
||||
| In Vitro Model | Lung adenocarcinoma | A549 cells | CVCL_0023 | ||
kR1020250008730A 99961.1-MMAE [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
11.08%
|
|||
| Method Description |
A xenograft model derived from cell lines was established by unilateral subcutaneous injection of 1×10^6 HT-29 cells into female Balb/C nude mice. When the tumor volume reached approximately 100 mm^3, 99961.1-MMAE was administered at a dose of 0.4 mg/kg. The treatment was given twice a week for 4 weeks. The tumor inhibition rate was calculated at the end of the experiment.
Click to Show/Hide
|
||||
| In Vivo Model | HT-29-xenograft model | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
15.90%
|
|||
| Method Description |
A xenograft model derived from cell lines was established by unilateral subcutaneous injection of 1×10^6 HT-29 cells into female Balb/C nude mice. When the tumor volume reached approximately 100 mm^3, 99961.1-MMAE was administered at a dose of 2 mg/kg. The treatment was given twice a week for 4 weeks. The tumor inhibition rate was calculated at the end of the experiment.
Click to Show/Hide
|
||||
| In Vivo Model | HT-29-xenograft model | ||||
| Experiment 3 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
34.60%
|
|||
| Method Description |
A xenograft model derived from cell lines was established by injecting 1×10^7 Jeko cells subcutaneously into the left side of female Balb/C nude mice. When the tumor volume reached approximately 100 mm^3, 99961.1-MMAE at doses of 2.5 mg/kg and 3.5 mg/kg was administered on the 15th and 29th days respectively. The tumor inhibition rate was calculated at the end of the experiment.
Click to Show/Hide
|
||||
| In Vivo Model | Jeko-1-xenograft model | ||||
| Experiment 4 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
37.81%
|
|||
| Method Description |
A xenograft model derived from cell lines was established by unilateral subcutaneous injection of 1×10^6 A549 cells into female Balb/C nude mice. When the tumor volume reached approximately 100 mm^3, 99961.1-MMAE was administered at a dose of 10 mg/kg. The treatment was given twice a week for 3 weeks. The tumor inhibition rate was calculated at the end of the experiment.
Click to Show/Hide
|
||||
| In Vivo Model | A549-xenograft model | ||||
| Experiment 5 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
59.22%
|
|||
| Method Description |
A xenograft model derived from cell lines was established by injecting 1×10^7 Jeko cells subcutaneously into the left side of female Balb/C nude mice. When the tumor volume reached approximately 100 mm^3, 99961.1-MMAE was administered at a dose of 2.5 mg/kg. The treatment was given once a week for 3 weeks. The tumor inhibition rate was calculated at the end of the experiment.
Click to Show/Hide
|
||||
| In Vivo Model | Jeko-1-xenograft model | ||||
| Experiment 6 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
64.31%
|
|||
| Method Description |
A xenograft model derived from cell lines was established by injecting 1×10^7 MDA-MB-468 cells subcutaneously into female BALB/C nude mice. When the tumor volume reached approximately 100 mm^3, 99961.1-MMAE was administered at a dose of 10 mg/kg once. The tumor inhibition rate was calculated at the end of the experiment.
|
||||
| In Vivo Model | MDA-MB-468-xenograft model | ||||
| Experiment 7 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
67.66%
|
|||
| Method Description |
A xenograft model derived from the cell line was established by injecting 1×10^6 MDA-MB-231 cells subcutaneously into the left side of female Balb/C nude mice. When the tumor volume reached approximately 100 mm^3, B31-H3L3-MMAE was administered at a dose of 5 mg/kg. The treatment was given once a week for 3 weeks. The tumor inhibition rate was calculated at the end of the experiment.
Click to Show/Hide
|
||||
| In Vivo Model | MDA-MB-231-xenograft model | ||||
| Experiment 8 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
89.35%
|
|||
| Method Description |
A xenograft model derived from cell lines was established by unilateral subcutaneous injection of 1×10^6 HT-29 cells into female Balb/C nude mice. When the tumor volume reached approximately 100 mm^3, 99961.1-MMAE was administered at a dose of 10 mg/kg. The treatment was given twice a week for 4 weeks. The tumor inhibition rate was calculated at the end of the experiment.
Click to Show/Hide
|
||||
| In Vivo Model | HT-29-xenograft model | ||||
| Experiment 9 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
91.74%
|
|||
| Method Description |
A xenograft model derived from cell lines was established by injecting 1×10^7 Jeko-1 cells subcutaneously into the left side of female Balb/C nude mice. When the tumor volume reached approximately 100 mm^3, 99961.1-MMAE was administered at a dose of 10 mg/kg once. The tumor inhibition rate was calculated at the end of the experiment.
|
||||
| In Vivo Model | Jeko-1-xenograft model | ||||
| Experiment 10 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
95.77%
|
|||
| Method Description |
A xenograft model derived from cell lines was established by injecting 1×10^7 Jeko cells subcutaneously into the left side of female Balb/C nude mice. When the tumor volume reached approximately 100 mm^3, 99961.1-MMAE was administered at a dose of 10 mg/kg. The treatment was given once a week for 3 weeks. The tumor inhibition rate was calculated at the end of the experiment.
Click to Show/Hide
|
||||
| In Vivo Model | Jeko-1-xenograft model | ||||
| Experiment 11 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
96.60%
|
|||
| Method Description |
A xenograft model derived from the cell line was established by injecting 1×10^6 MDA-MB-231 cells subcutaneously into the left side of female Balb/C nude mice. When the tumor volume reached approximately 100 mm^3, 99961.1-MMAE was administered at a dose of 10 mg/kg. The treatment was given once a week for 3 weeks. The tumor inhibition rate was calculated at the end of the experiment.
Click to Show/Hide
|
||||
| In Vivo Model | MDA-MB-231-xenograft model | ||||
| Experiment 12 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
97.86%
|
|||
| Method Description |
A xenograft model derived from the cell line was established by injecting 1×10^6 NCI-N87 cells subcutaneously into the left side of female Balb/C nude mice. When the tumor volume reached approximately 100 mm^3, 99961.1-MMAE was administered at a dose of 5 mg/kg. The treatment was given once a week for 3 weeks. The tumor inhibition rate was calculated at the end of the experiment.
Click to Show/Hide
|
||||
| In Vivo Model | NCI-N87-xenograft model | ||||
| Experiment 13 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
98.21%
|
|||
| Method Description |
A xenograft model derived from the cell line was established by injecting 1×10^7 MDA-MB-468 cells subcutaneously into the left side of female Balb/C nude mice. When the tumor volume reached approximately 100 mm^3, 99961.1-MMAE was administered at a dose of 5 mg/kg. The treatment was given once a week for 4 weeks. The tumor inhibition rate was calculated at the end of the experiment.
Click to Show/Hide
|
||||
| In Vivo Model | MDA-MB-468-xenograft model | ||||
| Experiment 14 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
99.20%
|
|||
| Method Description |
A xenograft model derived from the cell line was established by injecting 1×10^6 NCI-N87 cells subcutaneously into the left side of female Balb/C nude mice. When the tumor volume reached approximately 100 mm^3, 99961.1-MMAE was administered at a dose of 10 mg/kg. The treatment was given once a week for 3 weeks. The tumor inhibition rate was calculated at the end of the experiment.
Click to Show/Hide
|
||||
| In Vivo Model | NCI-N87-xenograft model | ||||
| Experiment 15 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
100%
|
|||
| Method Description |
A xenograft model derived from the cell line was established by injecting 1×10^7 MDA-MB-468 cells subcutaneously into the left side of female Balb/C nude mice. When the tumor volume reached approximately 100 mm^3, 99961.1-MMAE was administered at a dose of 10 mg/kg. The treatment was given once a week for 4 weeks. The tumor inhibition rate was calculated at the end of the experiment.
Click to Show/Hide
|
||||
| In Vivo Model | MDA-MB-468-xenograft model | ||||
References